GlassScriptPhysician profile
George Timothy Park
NPI 1558369173
$808.08
in general payments reported to CMS, 2019-2025
14 companies · $60.21 in 2025
The $60.21 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $209 · 2021: $114 · 2022: $71.23 · 2023: $154 · 2024: $93.76 · 2025: $60.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $196.98 | 2022-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $100.10 | 2020-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $92.93 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $80.59 | 2019-2022 | |
| Novo Nordisk INC | $64.03 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $56.26 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.18 | 2020-2021 | |
| Glaxosmithkline, LLC. | $34.95 | 2021-2024 | Shingrix |
| Novartis Pharmaceuticals Corporation | $34.69 | 2019 | |
| Merck Sharp & Dohme LLC | $29.94 | 2021-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Corcept Therapeutics | $21.92 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $21.58 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.96 | 2021 | |
| Amgen INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.